Abstract: . . .  approaches to deal with the dilemmas faced by policy decision-makers, stakeholders and individuals. In addition, it will examine how public authorities and professional sectors can best take into account the ethical implications of life sciences and biotechnology . _______________________________________________________________________ &KDLU Joachim Fritz-Vannahme, Journalist, Die Zeit (D) 3DQHO Commission Margot Wallström,  . . .
. . .  fisheries, Philippe Busquin, Commissioner for research MEP Robert Goebbels (L-PSE), Chair of EP Temporary Committee on Human Genetics Member State Agneta Bladh, Secretary of State, Ministry for Education and Science (S) Int’l organisation Michael Oborne, Director, OECD _______________________________________________________________________ 9:00 Reports on the four Workshops 10:00 Panel and plenary discussion: Biotechnology . . .
. . .  Ministry for Education and Science (S) Int’l organisation Michael Oborne, Director, OECD _______________________________________________________________________ 9:00 Reports on the four Workshops 10:00 Panel and plenary discussion: Biotechnology policies in Europe - needs for action 12:30 End  . . .
. . .  and Science (S) Int’l organisation Michael Oborne, Director, OECD _______________________________________________________________________ 9:00 Reports on the four Workshops 10:00 Panel and plenary discussion: Biotechnology policies in Europe - needs for action 12:30 End  . . .
. . .  looking approaches that allow us to reduce the existing technological and commercial gaps with main competitors as well as to address the societal issues openly and inclusively. This session will allow the Commission to present its consultation document and set out the context for the conference. Conference participants will be invited to frame the issues. _______________________________________________________________________ &RQIHUHQFHRSHQLQJ Erkki . . .
. . .  The public and stakeholders represent a wide range of values, interests and knowledge, giving rise to difficult challenges in managing complex issues in our pluralistic societies. This session will discuss inclusive approaches to deal with the dilemmas faced by policy decision-makers, stakeholders and individuals. In addition, it will examine how public authorities and professional sectors can best take into account the ethical implications of life sciences and . . .
--2922,6,244,3061,14608